Get the Stockscreener App
65.19
1.71%
1.095
Halozyme Therapeutics Inc stock is traded at $65.19, with a volume of 737.99K.
It is up +1.71% in the last 24 hours and down -15.22% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$64.10
Open:
$64.26
24h Volume:
737.99K
Relative Volume:
0.38
Market Cap:
$7.63B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
21.59
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-2.65%
1M Performance:
-15.22%
6M Performance:
+8.26%
1Y Performance:
+23.01%
1-Day Range:
$64.10
$65.63
1-Week Range:
$63.78
$66.92
52-Week Range:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
65.19 | 7.50B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.71 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.68 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
How to build a dashboard for Halozyme Therapeutics Inc. stockQuarterly Investment Review & Advanced Technical Signal Analysis - newser.com
Oak Ridge Investments LLC Trims Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Castellan Group Has $832,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Strong And Rising: Halozyme Therapeutics Stock May Have More Upside - Forbes
Zacks Research Issues Negative Estimate for HALO Earnings - MarketBeat
What technical models suggest about Halozyme Therapeutics Inc.’s comebackWall Street Watch & Long-Term Capital Growth Ideas - newser.com
Using data tools to time your Halozyme Therapeutics Inc. exitQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Heatmap analysis for Halozyme Therapeutics Inc. and competitors2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Tectonic Advisors LLC Decreases Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Upgraded by Weiss Ratings to "Buy (B-)" Rating - MarketBeat
Key metrics from Halozyme Therapeutics Inc.’s quarterly data2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Halozyme Therapeutics Inc Stock Analysis and ForecastProtective Put Strategies & Budget Friendly Portfolio - earlytimes.in
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? - sharewise.com
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to Hold - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for HALO - MarketBeat
Halozyme Therapeutics (HALO): What Recent Gains Reveal About Its Current Valuation - Yahoo
Halozyme Therapeutics Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Halozyme Appoints New Chief Operating Officer - The Globe and Mail
Halozyme Therapeutics Names Cortney Caudill Chief Operating Officer - MarketScreener
Halozyme (HALO) Appoints New Chief Operating Officer - GuruFocus
Halozyme names Cortney Caudill as COO - TipRanks
Halozyme Therapeutics appoints Cortney Caudill as chief operating officer - Investing.com
Halozyme Therapeutics, Inc. Announces Appointment of Cortney Caudill as Senior Vice President and Chief Operating Officer, Effective October 1, 2025 - MarketScreener
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Nasdaq
Pattern recognition hints at Halozyme Therapeutics Inc. upsideEarnings Overview Summary & Risk Managed Trade Strategies - newser.com
FY2025 EPS Forecast for Halozyme Therapeutics Cut by Analyst - MarketBeat
How buybacks impact Halozyme Therapeutics Inc. stock valueWeekly Trade Summary & Technical Pattern Based Signals - newser.com
How geopolitical risks impact Halozyme Therapeutics Inc. (RV7) stock2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Stock Analysis & AI Based Trade Execution Alerts - newser.com
33,600 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by LGT Fund Management Co Ltd. - MarketBeat
111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme Announces Merger Agreement with Elektrofi - TipRanks
Halozyme Therapeutics says if deal is terminated under certain circumstances, co to pay Elektrofi reverse termination fee of $36 million - MarketScreener
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target - MSN
Research Analysts Set Expectations for HALO FY2026 Earnings - MarketBeat
Institutional scanner results for Halozyme Therapeutics Inc.2025 Top Gainers & Daily Price Action Insights - newser.com
Is it too late to sell Halozyme Therapeutics Inc.Market Growth Summary & Free High Return Stock Watch Alerts - newser.com
Public Employees Retirement System of Ohio Acquires 38,049 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Can volume confirm reversal in Halozyme Therapeutics Inc.July 2025 Gainers & Low Drawdown Investment Strategies - newser.com
Halozyme Therapeutics (NASDAQ:HALO) Shares Down 4.3% on Insider Selling - Defense World
What analysts say about Halozyme Therapeutics Inc RV7 stockStock Price Divergence & Small Investment Portfolio - earlytimes.in
Halozyme Acquires Elektrofi to Enhance Drug Delivery - MSN
Halozyme to acquire Elektrofi, a biopharma focused on drug delivery - MSN
Halozyme Therapeutics (NASDAQ:HALO) Trading Down 4.3% on Insider Selling - MarketBeat
HC Wainwright Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $90.00 - MarketBeat
HC Wainwright & Co. Maintains Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq
Halozyme stock price target raised to $90 from $85 at H.C. Wainwright - Investing.com
Halozyme eyes microparticles in $900m Elektrofi acquisition - Yahoo Finance
AMI Asset Management Corp Sells 16,475 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):